Puerto Colombia

Researchers are evaluating the effectiveness, safety, and tolerability of a combination treatment including adagrasib, pembrolizumab, and platinum-doublet chemotherapy compared to a placebo combined with pembrolizumab and platinum-doublet chemotherapy. This study focuses on adults with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation. The trial is a randomized, double-blind, phase 3 study designed to provide insights into treatment options for this specific lung cancer type. Participants receive either adagrasib plus pembrolizumab alongside platinum-doublet chemotherapy drugs such as carboplatin or cisplatin and pemetrexed, or they receive a placebo plus pembrolizumab and the same chemotherapy regimen. The dosages and schedules of these drugs are specified and administered on predetermined days. The trial compares these two treatment groups to understand better the impact of adding adagrasib to the existing pembrolizumab and chemotherapy treatment. Throughout the study, participants are closely monitored for progression-free survival and overall survival, assessed up to seven years using standardized criteria for tumor response. Regular imaging scans such as CT or MRI are used to measure disease status. Safety and tolerability are also evaluated during the study, with ongoing assessments to track adverse effects and treatment response. The total duration of follow-up allows for long-term observation of treatment outcomes and participant health.

This research aims to evaluate the safety and effectiveness of iza-bren, a bi-specific antibody-drug conjugate targeting EGFR and HER3 with a topoisomerase inhibitor, compared to the treatment of physician's choice (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, or capecitabine). The study focuses on patients with previously untreated, locally advanced, recurrent inoperable, or metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, HER2-negative breast cancer who are not eligible for anti-PD(L)1 or endocrine therapies. The trial is conducted in two phases, phase 2 and phase 3, to thoroughly assess these treatments.

Researchers are evaluating the effectiveness and safety of plozasiran in about 288 adults who have severe hypertriglyceridemia (high levels of triglycerides in the blood) and a history of at least two acute pancreatitis events, with at least one occurring within the last year before screening. This Phase 3 study compares plozasiran to a placebo in a double-blind manner to better understand its impact on reducing pancreatitis risk in this population. Participants will be randomly assigned to receive either plozasiran 25 mg or a matching placebo through subcutaneous injections every three months. They will be advised to continue a low-fat diet and maintain their usual lipid- and triglyceride-lowering medications throughout the study. After completing the double-blind treatment period or experiencing an acute pancreatitis event, participants will enter a 12-month open-label phase where all receive plozasiran 25 mg injections every three months. During the study, participants will be monitored for the time until their first confirmed acute pancreatitis event starting more than 10 days after the first dose, with follow-up lasting up to approximately 50 months. Researchers will assess treatment effects, safety, adherence to diet and medications, and overall participant health. The study includes regular evaluations to ensure participant safety and collect data on the treatment's impact on severe hypertriglyceridemia and pancreatitis risk.